METHOD FOR PREDICTION OF EFFICACY OF ANTIVIRAL THERAPY IN ADULT PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1b

• 1. 包含来自基因型1b的丙型肝炎病毒基因组的核酸的核酸构建物、和导入有该核酸构建物的丙型肝炎病毒基因组复制细胞、以及感染性丙型肝炎病毒颗粒的制备方法 [P] . 中国专利： CN103534351A . 2014-01-22
• 2. 一种慢性乙型肝炎抗病毒治疗应答疗效预测的引物以及试剂盒 [P] . 中国专利： CN110951915A . 2020-04-03
• 3. Reply by the reliability of the prediction to the standard two-antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C, genotype 1b [P] . 俄罗斯专利： RU2014132315A . 2016-02-20

  机译： 对聚乙二醇干扰素和利巴韦林标准治疗慢性丙型肝炎，基因型1b的标准两种抗病毒治疗的预测可靠性的回答

• 4. METHOD FOR PREDICTION OF RELIABILITY OF RESPONSE TO ROUTINE TWO-COMPONENT ANTIRETROVIRAL THERAPY WITH PEGYLATED INTERFERONS AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1B [P] . 俄罗斯专利： RU2578030C2 . 2016-03-20

  机译： 预测丙型肝炎C基因型1B患者用聚乙二醇化干扰素和利巴韦林对例行二元抗病毒治疗的常规方法

• 5. A method of predicting the efficacy of antiviral therapy in chronic hepatitis C in adults and children [P] . 俄罗斯专利： RU2014135196A . 2016-03-20

  机译： 预测成人和儿童慢性丙型肝炎抗病毒治疗疗效的方法

• 1. Features and role of lipid peroxidation in patients with chronic hepatitis C (genotype 1b) before and after antiviral therapy [J] . Константинов Дмитрий Юрьевич, Суздальцев Алексей Александрович Kazan Medical Journal . 2014,第5期
• 2. Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease [J] . Arai Taeang, Atsukawa Masanori, Tsubota Akihito, Hepatology research: the official journal of the Japan Society of Hepatology . 2018,第7期
• 3. Efficacy and safety of ombitasvir/ritonavir/paritaprevir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease [J] . Arai Taeang, Atsukawa Masanori, Ikegami Tadashi, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期
• 4. Genotype and Serotype Identification of Hepatitis B Virus in Chronic Hepatitis B Patients Treated with Telbivudine [C] . Y Purnamasari, Tien, Arimaswati, International Seminar on Smart Molecule of Natural Resources . 2020
• 5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010
• 6. Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b [O] . Meng Wang, Yi Zhang, Zhiqin Li, 2015
• 7. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals [O] . Hayato Kurata, Yoshihito Uchida, Jun-Ichi Kouyama, 2017

• 1. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2and 3 in northwest China [J] . Ying Yang ,Feng-Ping Wu ,Wen-Jun Wang . 世界胃肠病学杂志：英文版 . 2019,第44期
• 2. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b [J] . Daisuke Endo ,Kenichi Satoh ,Noritomo Shimada . 世界胃肠病学杂志：英文版 . 2017,第13期
• 3. Efficacy and Safety of Glecaprevir/Pibrentasvir in Combination Therapy in Chronic Hemodialysis Patients with Genotype 2 Hepatitis C Virus Infection [J] . Naoki Hotta . 肠胃病学期刊（英文） . 2019,第1期
• 4. Study of the Efficacy of Triple Therapy of Sofosbuvir, Pegylated INFalpha 2a and Ribavirin in Treatment of Chronic Hepatitis C Patients Genotype 4 with High Fibrosis [J] . Alaa Aboud . 肠胃病学期刊（英文） . 2017,第1期
• 5. Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy [J] . José Eymard Medeiros-Filho ,Isabel Maria Vicente Guedes de Carvalho Mello ,Joo Renato Rebello Pinho . 世界胃肠病学杂志：英文版 . 2006,第45期
• 6. 宿主IL28B基因型联合病毒基因型对慢性丙型肝炎抗病毒疗效的预测 [C] . 廖祥伟 ,Liao Xiang-wei ,Ling Yun . 第二届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议 . 2012
• 7. HCV 1b亚型NS5A氨基酸变异对慢性丙型肝炎抗病毒治疗的影响 [A] . 李京涛 . 2012